Hans van der Vliet
Chief Tech/Sci/R&D Officer en LAVA THERAPEUTICS N.V. .
Fortuna: 257 576 $ al 31/03/2024
Origen de la red de primer grado Hans van der Vliet.
| Entidad | Tipo de entidad | Industria | |
|---|---|---|---|
University of Amsterdam
32
| College/University | Other Consumer Services | 32 |
| Public Company | Biotechnology | 26 | |
Vrije Universiteit Amsterdam
18
| College/University | Other Consumer Services | 18 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Hans van der Vliet a través de su red personal
| Empresa | Sector | Personas relacionadas | Puesto principal |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| CELGENE | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Cephalon, Inc.
 Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| IMMUNOGEN, INC. | Biotechnology | Corporate Officer/Principal | |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Human Resources Officer | |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| RADIUS HEALTH, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
Healthcare Businesswomens Association
 Healthcare Businesswomens Association Miscellaneous Commercial ServicesCommercial Services Healthcare Businesswomens Association operates women healthcare associations. The company was founded by Diane Anderson, Peg Dougherty, Millicent Gryczka, Sheila Sinkking and Ruth Smith in 1977 and is headquartered in Fairfield, NJ. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| FORMA THERAPEUTICS HOLDINGS, INC. | Pharmaceuticals: Major | Human Resources Officer | |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal Consultant / Advisor | |
Van Lanschot Kempen Investment Management NV
 Van Lanschot Kempen Investment Management NV Investment ManagersFinance Van Lanschot Kempen Investment Management NV (Van Lanschot Kempen) is a specialist wealth manager headquartered in Amsterdam, Netherlands. The firm was founded in 1991 and was formerly known as Kempen Capital Management NV. They are a wholly-owned subsidiary of Van Lanschot Kempen NV (AMS: VLK). Van Lanschot Kempen administers Dutch pension funds and provides integral asset management for Dutch institutional clients. | Investment Managers | Portfolio Manager-Fixed Income Analyst-Equity Portfolio Manager-Fixed Income | |
| HOLLAND COLOURS NV | Chemicals: Specialty | Director/Board Member Director of Finance/CFO | |
| University of Oxford | College/University | Graduate Degree Corporate Officer/Principal Undergraduate Degree | |
| Boston University | College/University | Corporate Officer/Principal | |
Deloitte & Touche LLP
 Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Comptroller/Controller/Auditor Comptroller/Controller/Auditor | |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
Synvolux Therapeutics BV
 Synvolux Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Synvolux Therapeutics BV provides drug delivery services. It is specialized in transporting of DNA, RNA (siRNA and RNAi) and proteins to the target destination. The company was founded in 2002 and is headquartered in Leiden, the Netherlands. | Miscellaneous Commercial Services | Chief Executive Officer | |
| University of Cambridge | College/University | Masters Business Admin Doctorate Degree | |
| The Pennsylvania State University | College/University | Undergraduate Degree Undergraduate Degree | |
AM-Pharma Holding BV
 AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Director/Board Member | |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member Corporate Officer/Principal | |
| University of Twente | College/University | Doctorate Degree Corporate Officer/Principal Undergraduate Degree | |
| University of Utrecht | College/University | Graduate Degree Graduate Degree | |
Holland Capital Management BV
 Holland Capital Management BV Investment ManagersFinance Holland Capital Management BV (Holland Capital) is an independent private equity & venture capital firm founded in 1981. The firm is headquartered in Amsterdam, the Netherlands. | Investment Managers | Private Equity Investor Public Communications Contact | |
| REPLIMUNE GROUP, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| AUTOLUS THERAPEUTICS PLC | Biotechnology | Director/Board Member Director/Board Member | |
| IMMUNOCORE HOLDINGS PLC | Biotechnology | Founder Chief Operating Officer | |
| Swiss Federal Institute of Technology | College/University | Doctorate Degree Graduate Degree | |
| ABN AMRO BANK N.V. | Major Banks | Chairman General Counsel | |
Standard Investment Management BV
 Standard Investment Management BV Investment ManagersFinance Standard Investment Management BV (Standard Investment) is a private equity firm founded in 2004 by Idgar van Kippersluis and Hendrik Jan ten Have. The firm is headquartered in Amsterdam, the Netherlands with additional offices in Etterbeek, Belgium and Stockholm, Sweden. | Investment Managers | Founder Founder | |
| INSEAD | College/University | Masters Business Admin Masters Business Admin | |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor Private Equity Investor | |
Amphista Therapeutics Ltd.
 Amphista Therapeutics Ltd. BiotechnologyHealth Technology Amphista Therapeutics Ltd. is a biopharmaceutical company based in Biocity Glasgow, UK. The British company is focused on creating first-in-class therapeutics that selectively and efficiently degrade and remove disease-causing proteins using targeted protein degradation (TPD). The company's pipeline of novel small molecules is focused on challenging diseases, including cancer. Amphista is a spin-out of Professor Alessio Ciulli's labs at the University of Dundee and is funded by leading life science investors, including Advent Life Sciences, the European Investment Fund, the Scottish Investment Bank, and Biomotiv. The CEO of the company is Nicola Thompson. | Biotechnology | Director/Board Member Director/Board Member | |
| Amsterdam Center for Corporate Finance | Founder | ||
AstraZeneca Pharmaceuticals LP
 AstraZeneca Pharmaceuticals LP Pharmaceuticals: MajorHealth Technology AstraZeneca Pharmaceuticals LP develops, manufactures and markets prescription pharmaceutical drugs. It sells products related to gastrointestinal, cardiovascular, neuroscience, respiratory and oncology infections. The company was founded in 1953 and is headquartered in Wilmington, DE. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| University of Sheffield Medical School | College/University | Doctorate Degree | |
| CELYAD ONCOLOGY SA | Biotechnology | Chief Tech/Sci/R&D Officer | |
Akamis Bio Ltd.
 Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Biotechnology | Corporate Officer/Principal | |
| The Royal College of Physicians | College/University | Corporate Officer/Principal | |
| University of Maine School of Law | College/University | Undergraduate Degree |
Estadísticas
Internacional
| Estados Unidos | 17 |
| Países Bajos | 14 |
| Reino Unido | 9 |
| Alemania | 3 |
| Israel | 2 |
Sectorial
| Health Technology | 19 |
| Consumer Services | 12 |
| Finance | 7 |
| Commercial Services | 6 |
| Process Industries | 2 |
Operativa
| Director/Board Member | 256 |
| Corporate Officer/Principal | 127 |
| Graduate Degree | 54 |
| Director of Finance/CFO | 49 |
| Chairman | 40 |
Las relaciones más conectadas
| Insiders | |
|---|---|
| James Noble | 39 |
| Kapil Dhingra | 39 |
| Ralf Wessel | 33 |
| Karen Wilson | 31 |
| Nanna Liebach Lüneborg | 29 |
| Peter Kiener | 25 |
| Stephen DiPalma | 24 |
| Guido Magni | 23 |
| Simon Pimstone | 22 |
| Steven ten Have | 18 |
| Joël Jean-Mairet | 17 |
| Stephen Allen Hurly | 16 |
| Jay Backstrom | 15 |
| Erik van den Berg | 13 |
| Arnoud W. A. Boot | 13 |
- Bolsa de valores
- Insiders
- Hans van der Vliet
- Conexiones Empresas
